CN104039313A - 缓释制剂 - Google Patents

缓释制剂 Download PDF

Info

Publication number
CN104039313A
CN104039313A CN201280062591.4A CN201280062591A CN104039313A CN 104039313 A CN104039313 A CN 104039313A CN 201280062591 A CN201280062591 A CN 201280062591A CN 104039313 A CN104039313 A CN 104039313A
Authority
CN
China
Prior art keywords
pioglitazone
sustained
polyethylene oxide
average molecular
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062591.4A
Other languages
English (en)
Chinese (zh)
Inventor
田上宽
村川佑介
石井友美子
竹中薰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104039313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN104039313A publication Critical patent/CN104039313A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280062591.4A 2011-10-21 2012-10-19 缓释制剂 Pending CN104039313A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-232302 2011-10-21
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
CN104039313A true CN104039313A (zh) 2014-09-10

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062591.4A Pending CN104039313A (zh) 2011-10-21 2012-10-19 缓释制剂

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG2014012025A (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
EP3070081B1 (en) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
US20150141517A1 (en) 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091004A (zh) * 1992-09-18 1994-08-24 山之内制药株式会社 水凝胶缓释剂
WO2000032190A1 (en) * 1998-11-27 2000-06-08 Case Western Reserve University Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
CN101884627A (zh) * 2010-07-07 2010-11-17 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
CN102170878A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 控释药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
CN1802178A (zh) 2003-06-06 2006-07-12 武田药品工业株式会社 固体制剂
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CA2578474A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
EP1940403A2 (en) 2005-09-22 2008-07-09 SB Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
ES2744495T3 (es) 2006-03-30 2020-02-25 Nippon Zoki Pharmaceutical Co Preparación farmacéutica sólida
AR060663A1 (es) 2006-04-27 2008-07-02 Takeda Pharmaceutical Composicion farmaceutica solida
HRP20141008T1 (hr) 2007-02-09 2015-01-02 Alphapharm Pty Ltd Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
CA2738930C (en) 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
CN102548544B (zh) 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
AU2012205798B2 (en) * 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091004A (zh) * 1992-09-18 1994-08-24 山之内制药株式会社 水凝胶缓释剂
WO2000032190A1 (en) * 1998-11-27 2000-06-08 Case Western Reserve University Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
CN102170878A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 控释药物组合物
CN101884627A (zh) * 2010-07-07 2010-11-17 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王文苹 等: "聚氧乙烯骨架缓释片的处方及体外释药机制研究", 《中国现代应用药学》 *
聂淑芳 等: "聚氧乙烯亲水凝胶骨架片的溶蚀行为", 《药学学报》 *

Also Published As

Publication number Publication date
IN2014DN03169A (enExample) 2015-05-22
PE20141189A1 (es) 2014-09-24
BR112014008744A2 (pt) 2017-04-18
AR088398A1 (es) 2014-05-28
EA201490840A1 (ru) 2014-08-29
US9907789B2 (en) 2018-03-06
KR20140081826A (ko) 2014-07-01
WO2013058409A1 (en) 2013-04-25
IL232114A0 (en) 2014-06-30
AU2012326976A1 (en) 2014-05-29
EP2768487A1 (en) 2014-08-27
ZA201403103B (en) 2015-08-26
TW201323018A (zh) 2013-06-16
PH12014500856A1 (en) 2014-05-19
DOP2014000077A (es) 2014-07-15
AP2014007645A0 (en) 2014-05-31
TN2014000152A1 (en) 2015-09-30
CA2852417A1 (en) 2013-04-25
UA113858C2 (uk) 2017-03-27
CR20140213A (es) 2014-06-18
MX2014004679A (es) 2014-08-01
US20140248362A1 (en) 2014-09-04
SG10201700121YA (en) 2017-03-30
JP6093762B2 (ja) 2017-03-08
CO6960544A2 (es) 2014-05-30
UY34403A (es) 2013-05-31
AU2012326976A2 (en) 2014-06-12
JP2014530802A (ja) 2014-11-20
NZ624275A (en) 2016-09-30
ECSP14013328A (es) 2014-05-31
SG2014012025A (en) 2014-06-27
MA35717B1 (fr) 2014-12-01
AU2012326976B2 (en) 2017-08-17
CL2014000992A1 (es) 2014-09-05
EP2768487B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JP4688089B2 (ja) 放出制御医薬組成物
CN104039313A (zh) 缓释制剂
CN101969931A (zh) 包含霉酚酸的调节释放药物组合物及其方法
JPWO2014034860A1 (ja) 経口投与用医薬組成物
JP2023513249A (ja) オメカムチブメカルビル製剤
JP2016188181A (ja) ミラベグロン含有放出制御錠剤
CN103945831A (zh) 医药制剂
TW202038917A (zh) 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法
EP2987489A1 (en) Controlled-release drug formulation
CN102958514A (zh) 口腔内崩解片剂
JP2017523149A (ja) エドキサバンの医薬組成物
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
US10420764B2 (en) Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
US10335376B2 (en) Raloxifene sprinkle composition
TW201729814A (zh) 固形製劑
HK1212229B (en) Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication